Abstract
The aberrant aggregation of proteins is a key molecular event in the development and progression of a wide range of neurodegenerative disorders. We have shown previously that squalamine and trodusquemine, two natural products in the aminosterol class, can modulate the aggregation of the amyloid-β peptide (Aβ) and of α-synuclein (αS), which are associated with Alzheimer's and Parkinson's diseases. In this work, we expand our previous analyses to two squalamine derivatives, des-squalamine and α-squalamine, obtaining further insights into the mechanism by which aminosterols modulate Aβ and αS aggregation. We then characterize the ability of these small molecules to alter the physicochemical properties of stabilized oligomeric species in vitro and to suppress the toxicity of these aggregates to varying degrees toward human neuroblastoma cells. We found that, despite the fact that these aminosterols exert opposing effects on Aβ and αS aggregation under the conditions that we tested, the modifications that they induced to the toxicity of oligomers were similar. Our results indicate that the suppression of toxicity is mediated by the displacement of toxic oligomeric species from cellular membranes by the aminosterols. This study, thus, provides evidence that aminosterols could be rationally optimized in drug discovery programs to target oligomer toxicity in Alzheimer's and Parkinson's diseases.
Introduction
Neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s (PD) are characterized by the misfolding and clumping of specific proteins: Amyloid-β (Aβ) and α-Synuclein (αS), respectively. While large protein fibrils were once thought to be the primary drivers of pathology, current research identifies small, intermediate clumps called oligomers as the most toxic species. These oligomers disrupt cellular membranes, leading to neuronal death.
Aminosterols—natural compounds originally identified in shark liver—have shown promise in protecting neurons from these toxic aggregates. This study investigates squalamine and its derivatives to understand how subtle chemical modifications influence their ability to modulate protein aggregation and neutralize oligomer toxicity.
Methods
The researchers employed a multi-disciplinary approach to track protein behavior from molecular interactions to cellular outcomes:
- Chemical Kinetics: Thioflavin-T (ThT) fluorescence assays monitored protein aggregation rates in real-time.
- Biophysical Imaging: Atomic Force Microscopy (AFM) and Transmission Electron Microscopy (TEM) visualized the morphology of protein fibrils.
- Structural Characterization: ANS binding assays measured surface hydrophobicity, while turbidity measurements assessed aggregate size.
- Cellular Assays: Toxicity was evaluated on human SH-SY5Y neuroblastoma cells using MTT reduction assays.
- Confocal Microscopy: High-resolution imaging quantified the displacement of protein oligomers from cell membranes by the aminosterols.
Key Insights: Structure-Activity Relationships
The study highlights how specific chemical features of aminosterols dictate their efficacy. Two primary compounds, Squalamine (SQ) and Trodusquemine (TRO), along with derivatives des-squalamine (desSQ) and α-squalamine (αSQ), were compared.
A critical finding was the role of the polyamine side chain. Trodusquemine (TRO) was found to be 3 to 10 times more potent than Squalamine (SQ). This increased potency is attributed to TRO's "spermine" side chain, which carries a +3 charge, compared to the +2 charge of SQ's "spermidine" chain. This higher positive charge facilitates more effective binding to negatively charged components of the cell membrane, thereby displacing toxic oligomers more efficiently.
Furthermore, the sulfate group was identified as essential; its removal in des-squalamine significantly reduced the molecule's protective capabilities.
Results and Discussion
Opposing Kinetic Effects
Interestingly, aminosterols exert opposite effects on the aggregation kinetics of Aβ and αS. They accelerate Aβ42 aggregation, effectively pushing the protein past the toxic oligomer stage into inert fibrils. Conversely, they inhibit the initiation of αS aggregation.
The Membrane Displacement Mechanism
Despite these kinetic differences, the primary protective mechanism is shared: membrane displacement. By binding to the cell membrane, aminosterols outcompete toxic oligomers for binding sites. Confocal microscopy demonstrated that 10 µM of squalamine reduced Aβ42 oligomer binding to cell membranes by approximately 69%.
Toxicity Suppression
Squalamine and its derivatives successfully neutralized the toxicity of Aβ42, Aβ40, and HypF-N (a model misfolded protein) oligomers in human cell cultures. At high concentrations, these compounds also induced physical changes in the oligomers, causing them to cluster into larger, less hydrophobic, and less toxic aggregates.
Conclusion and Future Directions
While aminosterols show great potential, challenges remain. Squalamine does not effectively cross the blood-brain barrier (BBB), though trodusquemine has been reported to do so. Future research will focus on the rational optimization of these molecules to create synthetic derivatives with the high charge of TRO and improved drug-like properties, such as enhanced brain penetration and reduced systemic toxicity. This study provides a foundational understanding for targeting oligomer toxicity in Alzheimer's and Parkinson's diseases.
Summary updated